

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Sub.: **Outcome of Board Meeting held today, i.e. 28th October, 2025 –Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2025.**

Reg.: **Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Dear Sir,

1. The Standalone Unaudited Financial Statements for the quarter and half year ended on 30th September, 2025 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide their meeting held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, along with statement of standalone Assets & Liabilities as at 30th September, 2025 and Cash Flow statement for the half year ended on 30th September, 2025, as annexure A and B respectively.
2. The Limited Audit Review Report dated 28th October, 2025, of Auditors of the Company, on the standalone unaudited financial results for the quarter ended on 30th September, 2025, is also attached.

The Board Meeting commenced at 2.30 p.m. and was concluded at 04.15 p.m.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,


ASHISH R. SHAH
Sr. Vice President and Company Secretary



Encl.: As Stated Above.

Statement of Standalone Unaudited Financial Results for the Quarter & Half Year Ended on 30th September, 2025

(Rs. in Lacs other than EPS)

	Particulars	Quarter Ended			Year to Date		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	4555.76	3552.68	4121.59	8108.44	7375.16	15169.15
II	Other Income	207.90	205.71	185.33	413.61	325.90	672.10
III	Total income (I + II)	4763.66	3758.39	4306.92	8522.05	7701.06	15841.25
IV	Expenses						
(a)	Cost of Materials Consumed	219.35	213.54	214.53	432.89	398.30	851.12
(b)	Purchase of Stock-in-trade	628.33	537.24	532.82	1165.57	1108.05	2126.08
(c)	Changes in inventories of Finished Goods, Stock-in-trade and WIP	-12.04	-99.02	80.42	-111.06	-49.58	-11.55
(d)	Employee benefit expenses	1393.25	1172.08	1251.90	2565.33	2318.65	4553.58
(e)	Finance Costs	10.74	10.99	11.64	21.73	23.12	45.28
(f)	Depreciation and Amortisation Expense	74.39	72.25	63.90	146.64	115.80	272.79
(g)	Other expenses	1016.44	833.11	899.43	1849.55	1528.31	3610.67
	Total Expenses (IV)	3330.46	2740.19	3054.64	6070.65	5442.65	11447.97
V	Profit before tax (III - IV)	1433.20	1018.20	1252.28	2451.40	2258.41	4393.28
VI	Tax Expense						
(i)	Current Tax	400.00	200.00	300.00	600.00	550.00	1190.00
(ii)	Income Tax for previous years	0.00	0.00	0.00	0.00	0.00	17.80
(iii)	Deferred Tax	16.86	39.02	-7.77	55.88	6.76	-20.58
VII	Profit after tax for the period (V-VI)	1016.34	779.18	960.05	1795.52	1701.65	3206.06
VIII	Other Comprehensive Income						
A	(i) Items that will not be reclassified to profit or loss	-45.10	155.19	78.59	110.09	252.19	136.06
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	16.97	-17.76	21.93	-0.79	3.41	16.80
B	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
IX	Total Comprehensive Income for the period (VII + VIII)	988.21	916.61	1060.57	1904.82	1957.25	3358.92
	Paid up Equity Share Capital (F.V. Rs.10/- each)	441.33	441.33	441.33	441.33	441.33	441.33
X	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	23.03	17.66	21.75	40.68	38.56	72.65

Notes:


- The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 28th October 2025.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The Statement of Assets and Liabilities as at 30th September 2025 and Cashflow Statement for the half year ended on 30th September 2025 are annexed as Annexure A & B respectively.

Place : Mumbai

Date : 28th October 2025



For Jenburkt Pharmaceuticals Ltd.


(Ashish U. Bhuta)
Chairman & Managing Director
(DIN No: 00226479)

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Standalone Unaudited Statement of Assets and Liabilities as at 30th September, 2025

			Rs in Lacs	
	Particulars	Note	30/09/2025	31/03/2025
			Amount	Amount
	ASSETS			
(1)	Non-current Assets			
(a)	Property, Plants & Equipments	1	1142.35	1229.47
(b)	Right to Use Asset	2	190.14	213.44
(c)	Other Intangible assets	2	37.73	22.79
(d)	Capital Work In Progress	3	5221.20	4027.67
(e)	Financial Assets			
(i)	Investments	4	2725.93	2055.81
(ii)	Loans	5	1.30	1.90
(iii)	Other Financial Assets	6	6861.65	5990.89
	Deferred Tax Asset	7	80.19	146.93
(f)	Other Non-current Assets	8	109.16	276.54
(2)	Current assets			
(a)	Inventories	9	1017.49	888.03
(b)	Financial Assets			
(i)	Trade Receivables	10	2275.47	2073.49
(ii)	Cash and Cash Equivalents	11	543.50	736.48
(iii)	Bank Balance other than (iii)	12	421.33	1728.11
(iv)	Loans	13	39.15	5.20
(v)	Other Financial Assets	14	37.10	40.30
(c)	Other Current Assets	15	187.29	165.73
	Current Tax Asset (Net)	16	15.81	15.81
	Total Assets		20,906.79	19,618.60
	EQUITY AND LIABILITIES			
(1)	Equity			
(a)	Equity Share Capital	17	441.33	441.33
(b)	Other Equity - Reserves & Surplus	18	17,846.80	16,736.38
	Liabilities			
(2)	Non-current liabilities			
(a)	Financial Liabilities			
(i)	Lease Liabilities	19	126.73	149.19
(ii)	Other Financial Liabilities	20	301.03	301.03
(b)	Deferred Tax Liability	7	98.67	108.74
(3)	Current Liabilities			
(a)	Financial Liabilities			
(i)	Lease Liabilities	21	44.03	42.31
(ii)	Borrowings	22	-	197.88
(iii)	Trade Payables			
(A)	Total Outstanding dues of Micro Enterprises and Small Enterprises; and	23	20.36	16.56
(B)	Total Outstanding dues of creditors other than Micro Enterprises and Small Enterprises.	23	933.84	798.97
(iv)	Other Financial Liabilities	24	658.19	467.93
(b)	Other Current Liabilities	25	167.49	169.29
(c)	Provisions	26	103.36	160.40
(d)	Current Tax Liabilities (Net)	16	164.94	28.59
	Total Equity and Liabilities		20,906.79	19,618.60

By order of the Board

For Jenburkt Pharmaceuticals Ltd.



(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

(DIN No: 00226479)

Place : Mumbai

Date : 28th October, 2025

Unaudited Cashflow Statement for the half year ended on 30th September, 2025

Rs in Lacs

		30-09-2025	31-03-2025
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a	Net Profit After Tax	1,795.51	3,206.06
	Adjustments for :		
i	Depreciation and Amortisation Expense	146.64	272.79
ii	Loss on Fixed Assets scrapped	0.19	3.39
iii	Tax Expense	655.88	1,187.22
iv	Finance Cost	21.73	45.28
v	Interest Income	(279.02)	(526.22)
vi	Dividend income	(7.19)	(8.73)
vii	Unrealised Gain on Investment at Fair Value	0.28	(5.17)
viii	Gain on sale of investment (Short Term Capital Gain / Loss)	(23.29)	(80.59)
ix	Provision/write off for doubtful trade receivables/advances	(187.42)	7.92
x	Unrealised Foreign Exchange gain	(64.52)	(19.36)
xi	Others	0.96	1.92
	Operating profit (Loss) before working capital changes	2,059.75	4,084.49
b	MOVEMENTS IN WORKING CAPITAL		
i	Increase or (Decrease) in Inventories	(129.47)	(31.86)
ii	Increase or (Decrease) in Trade Receivables	49.95	(114.53)
iii	Increase or (Decrease) in Other (Current & Non Current) Assets	145.99	(141.33)
iv	Increase or (Decrease) in Trade Payables	138.67	189.81
v	Increase or (Decrease) in Bank Borrowings	(197.88)	197.88
vi	Increase or (Decrease) in Other (Current & Non Current) Liabilities	197.73	(114.30)
vii	Current & Non Current Financial Loans	(33.35)	4.99
viii	Increase or (Decrease) in Provisions	(57.04)	58.74
c	Cash used in operation	2,174.36	4,133.91
i	Income Taxes paid (Net of Refund)	(463.65)	(1,343.31)
	Net cash used in operating activities (A)	1,710.71	2,790.60
B.	CASH FLOW FROM INVESTING ACTIVITIES :		
i	Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in Development)	(1,244.87)	(1,971.36)
ii	Proceeds from disposal of property, plant and equipment and intangible assets	-	-
ii	Purchase of Investments	(2,951.93)	(3,762.77)
iii	Proceeds from Sale / Redemption of Investments	2,414.91	3,616.29
iv	Other Bank balances not considered as cash and cash equivalents		
	- Bank Fixed Deposit made during the year	(5,349.00)	(15,287.38)
	- Bank Fixed Deposit matured during the year	5,959.93	15,155.72
v	Interest Received	108.22	536.30
vi	Dividend Received	7.19	8.73
	Net cash generated by investing activities (B)	(1,055.55)	(1,704.47)
C.	CASH FLOW FROM FINANCING ACTIVITIES :		
i	Finance Cost	(22.79)	(28.04)
ii	Dividend paid	(797.30)	(678.05)
iii	Repayment of Lease Liabilities	(28.05)	(56.10)
	Net cash used in financing activities (C)	(848.14)	(762.19)
	NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)	(192.98)	323.94
	Cash and cash equivalent at the beginning of the year (1st April, 2024)	736.48	412.54
	Cash and cash equivalent as at the end of the year (30th September, 2025)	543.50	736.48
		(192.98)	323.94

By order of the Board

For Jenburkt Pharmaceuticals Ltd.



 (ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai

Date : 28th October, 2025

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034

TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30th September 2025 (the statement).


This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)



Partner

Vikram Mehta

(Membership No. 47347)

UDIN: **25047347BMKQID6215**

Place: Mumbai

Date: 28th October 2025

